In a significant move that underscores the evolving landscape of cross-border pharmaceutical development, Expedition Therapeutics announced this Wednesday that it has successfully closed a $115 million Series B financing round. The capital infusion is earmarked to propel the company’s lead experimental drug candidate, EXPD-101, through critical mid-stage clinical testing.
Expedition, a biotech startup established in 2024, operates on a strategic model that has gained rapid traction among venture capitalists: identifying and in-licensing high-potential drug assets from Chinese pharmaceutical companies to shepherd them through rigorous global clinical trials. By leveraging the vast, often untapped research and development output from China’s innovative biopharma sector, Expedition is positioning itself as a vital conduit between Eastern discovery and Western commercialization.
The Core Asset: Targeting Neutrophilic Inflammation
At the heart of Expedition’s pipeline is EXPD-101 (formerly known as XH-S004), an asset originally developed by Fosun Pharma. The drug is a small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1), an enzyme that plays a pivotal role in the activation of neutrophils—the most abundant type of white blood cell in humans.
While neutrophils are essential for the body’s innate immune defense against pathogens, their overactivation is a known driver of chronic, destructive inflammation in the lungs. In conditions like Chronic Obstructive Pulmonary Disease (COPD), this hyper-responsiveness leads to long-term tissue damage and impaired respiratory function. By modulating DPP1, Expedition aims to stifle this inflammatory cascade at its source, potentially offering a disease-modifying approach rather than merely managing symptoms.
Chronology of Expedition’s Rapid Ascent
The trajectory of Expedition Therapeutics has been characterized by speed and strategic focus.
- Early 2024: Expedition Therapeutics is founded with a mandate to bridge the gap between Chinese innovation and global therapeutic needs.
- Late 2024: The company secures a robust $165 million Series A round, signaling strong investor confidence in its business model.
- Late 2024/Early 2025: Expedition signs its inaugural landmark deal with Fosun Pharma, acquiring global rights (excluding certain regions) to the DPP1 inhibitor, EXPD-101.
- Mid-2025: The company begins recruitment for a global Phase 2 clinical trial, marking the first time a DPP1 inhibitor has been subjected to such a broad study in the context of COPD.
- Early 2026: The company announces the successful $115 million Series B round, with participation from major institutional players including General Atlantic, Vivo Capital, and Novo Holdings.
Supporting Data and the Competitive Landscape
The race to treat COPD has intensified as new biological understandings have emerged. Expedition is entering a crowded but high-reward field. Insmed, a prominent player in this space, previously licensed a DPP1 inhibitor from AstraZeneca, which has since been brought to market as Brinsupri for bronchiectasis—a drug widely expected to achieve blockbuster status.
Furthermore, industry heavyweights such as Boehringer Ingelheim, as well as collaborative efforts between Chiesi and Haisco Pharmaceutical, are actively exploring DPP1 inhibition. This competitive fervor validates the mechanism of action, but it also forces Expedition to differentiate itself.
CEO Yi Larson, a veteran of the biotech industry with a pedigree including Turning Point Therapeutics and LianBio, argues that EXPD-101 possesses unique advantages. "You take this pill once a day, and it can target that underlying inflammation that all the COPD patients have," Larson noted. "This felt like it could become a backbone of care for patients."
Unlike biologics, which often require intravenous administration and are confined to specific patient subsets, EXPD-101 is an oral small molecule. Larson believes this convenience, combined with its ability to address the "whole population" of COPD patients suffering from neutrophilic inflammation, positions the drug as a potential standard-of-care shift.
Strategic Implications of the China-to-Global Pipeline
The success of Expedition’s fundraising effort is not an isolated event; it is a manifestation of a broader trend. Investors are increasingly looking to China as a hub for "first or best-in-class" assets. General Atlantic, which led the Series B round, has been instrumental in this movement.
Brett Zbar, a managing director at General Atlantic, noted that the firm has "benefited from the good fortune of having a team and a real presence in China." This local presence allows investors to conduct deeper due diligence on Chinese assets that might otherwise be overlooked by Western firms lacking on-the-ground expertise.
This strategy is not without its risks, particularly in an era of shifting geopolitical tensions. However, for companies like Expedition, the benefits—gaining access to a pipeline of assets that have already shown promise in initial trials—outweigh the regulatory hurdles. By acting as the "bridge," Expedition provides a path to the U.S. and European markets that Chinese developers might struggle to navigate alone.
Leadership and Institutional Backing
The confidence of the investment community is also tied to the leadership team. Yi Larson’s background as a former Goldman Sachs investment banker turned executive at companies acquired by Bristol Myers Squibb (Turning Point and RayzeBio) provides the company with a unique blend of financial acumen and clinical development expertise.
The Series B round was not only led by General Atlantic but featured a deep bench of sophisticated biotech investors, including:
- RA Capital Management
- Forbion
- Sofinnova Investments
- Novo Holdings
- Venrock
- Vivo Capital
The inclusion of these firms suggests a long-term commitment to Expedition’s platform rather than a short-term liquidity play. As part of the investment, Brett Zbar will join the Expedition board, providing strategic oversight as the company moves into the critical data-generation phase of its lifecycle.
Looking Ahead: The 2028 Horizon
The roadmap for Expedition is now clearly defined by the federal clinical trial database, which indicates that initial Phase 2 data is expected in 2028. These results will serve as a "make-or-break" moment for the company.
If the trial succeeds in demonstrating both safety and efficacy in reducing the frequency of COPD exacerbations, EXPD-101 will likely become one of the most sought-after assets in the respiratory space. Should it fail, it would raise questions about the efficacy of the DPP1 class in broad COPD populations, potentially impacting the valuations of other startups betting on similar mechanisms.
For now, the momentum is firmly in Expedition’s favor. By addressing one of the world’s most common and debilitating inflammatory conditions with a convenient, oral pill, the company has staked a claim on a massive, underserved market. As the industry watches, the "Expedition model" of cross-border drug development will face its most rigorous test yet: transforming a promising clinical candidate into a global medical reality.
In a sector where failures are common and development timelines are notoriously long, Expedition Therapeutics is attempting to compress the cycle, proving that with the right capital, the right partners, and the right asset, the distance between a Chinese lab and a patient’s medicine cabinet can be significantly narrowed.
About the Author
